Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational therapeutic sonelokimab [3]. Clinical Trials and Data - The company conducted Phase 3 VELA trials for sonelokimab, claiming strong clinical data from its Phase 2 MIRA trial that suggested higher clinical responses and differentiation from competitors [4]. - Allegations have emerged that the clinical data and Nanobody structure of sonelokimab do not provide a superior clinical benefit compared to competitors, raising concerns about the drug's regulatory approval and commercial viability [5]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share within a few days [6].

Core Points - A shareholder has filed a securities class action lawsuit on behalf of investors who purchased or acquired common stock of MoonLake Immunotherapeutics between March 10, 2024, and September 29, 2025 [1] - The lawsuit alleges that the defendants made misrepresentations regarding the company's sole drug candidate, sonelokimab (SLK), which was claimed to be superior to competing monoclonal antibody drugs [3] Legal Proceedings - Investors wishing to serve as lead plaintiff must file papers by December 15, 2025, and representation is on a contingency fee basis, meaning shareholders pay no fees or expenses [4] - The law firm Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its success in litigating class actions [5]

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of MoonLake Immunotherapeutics common stock during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and statements [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that the defendants made false or misleading statements regarding the efficacy and clinical benefits of their product SLK compared to traditional monoclonal antibodies [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4]. - The Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [4]. - A lead plaintiff must move the Court by December 15, 2025, to represent other class members in the litigation [1][3]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - No class has been certified yet, meaning investors are not represented unless they retain counsel [7]. - Investors can choose to remain absent from the class and still have the potential to share in any future recovery [7].

Core Viewpoint - MoonLake Immunotherapeutics is under investigation for potential violations of federal securities laws, which may have impacted investors negatively [1]. Company Investigation - The Law Offices of Frank R. Cruz are leading the investigation on behalf of investors who may have suffered losses related to MoonLake Immunotherapeutics [1]. - The investigation was prompted by a disappointing announcement made by the company on September 28, 2025 [1].

Core Viewpoint - An investigation has been announced regarding MoonLake Immunotherapeutics for potential violations of federal securities laws, indicating possible legal issues that could affect investors [1]. Company Summary - MoonLake Immunotherapeutics is under scrutiny for its compliance with federal securities regulations, which may have implications for its investors [1]. - The Law Offices of Howard G. Smith are reaching out to investors who have experienced losses in MoonLake (MLTX) to discuss potential claims for recovery [1].

Core Viewpoint - Glancy Prongay & Murray LLP has initiated an investigation into MoonLake Immunotherapeutics regarding potential violations of federal securities laws, indicating concerns over the company's compliance and investor losses [1]. Summary by Relevant Sections - **Company Overview** - MoonLake Immunotherapeutics is listed on NASDAQ under the ticker MLTX [1]. - **Investigation Details** - The investigation is on behalf of investors who may have suffered financial losses related to MoonLake [1]. - The law firm is reaching out to investors to explore the possibility of pursuing claims to recover losses [1].

Core Viewpoint - Marex Group PLC is facing a class action lawsuit for allegedly misleading investors about its revenue projections and inflating its financial metrics through improper accounting practices [2][3]. Group 1: Company Overview - Marex Group PLC is a U.K.-based diversified global financial services platform listed on NASDAQ under the ticker MRX [1]. Group 2: Legal Allegations - The lawsuit claims that Marex Group failed to disclose that it improperly inflated its cash flow, revenues, assets, and profits in its Market Making segment through off-book intercompany transactions [3]. - As a result of these alleged actions, investors who sold short Marex Group securities during the class period have reportedly suffered significant losses [2][3]. Group 3: Class Action Details - The class period for the lawsuit is defined as August 14, 2024, to August 5, 2025 [2]. - Shareholders interested in serving as lead plaintiffs must submit their papers to the court by December 8, 2025 [4]. - Participation in the class action is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors about the safety of its Novum LVP device, which has been linked to serious malfunctions and risks to patient safety [2][3]. Allegations - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP device, which led to malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures, leading to continued harm [2]. - The company’s statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were allegedly materially false and misleading [2]. Stock Impact - Following the announcement on July 31, 2025, regarding the suspension of all new Novum LVP sales, Baxter's stock price dropped by 22.4%, closing at $21.76 [3]. Class Action Participation - Shareholders interested in participating in the class action must submit their papers by December 15, 2025, to serve as lead plaintiff [4].

Core Points - A class action has been filed against MoonLake Immunotherapeutics on behalf of investors who purchased its common stock between March 10, 2024, and September 29, 2025 [1] - The allegations include misleading statements regarding the efficacy of MoonLake's drug candidate SLK compared to the FDA-approved drug BIMZELX [2] - On September 28, 2025, MoonLake announced that SLK failed to demonstrate competitive efficacy relative to BIMZELX, resulting in a significant stock price drop of $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [3] Allegations - The complaint states that MoonLake misled investors about the differences between Nanobodies and monoclonal antibodies, specifically regarding SLK's clinical benefits and efficacy [2] - Key points of the allegations include that SLK and BIMZELX target the same inflammatory cytokines, and that SLK's unique structure does not provide a clinical advantage over BIMZELX [2] Next Steps - Shareholders interested in participating in the class action must submit their papers to the court by December 15, 2025, to serve as lead plaintiff [4] - Shareholders can remain absent class members if they choose not to participate in the case [4]

Core Viewpoint - The lawsuit claims that the defendants made false statements regarding MoonLake's business and prospects, leading to inflated stock prices [1] Company Summary - The allegations suggest that misleading information was disseminated about MoonLake, impacting investor perception and stock valuation [1]